Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.22 USD | +9.75% | +10.48% | +39.80% |
05-23 | Cogent Reports Positive Cancer Combo Treatment Trial Data; Names Commercial Chief | MT |
05-23 | Cogent Biosciences, Inc. Announces the Appointment of Cole Pinnow as Chief Commercial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.80% | 716M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- Wedbush Adjusts Cogent Biosciences Price Target to $20 From $17, Maintains Outperform Rating